Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 6, 1998, Pages 672-681

  Panara, Maria R ^b   Padovano, Roberto ^b   Sciulli, Maria G ^b   Santini, Giovanna ^b   Renda, Giulia ^b   Rotondo, Maria T ^b   Pace, Annamaria ^b   Patrono, Carlo ^b   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; 6 OXOPROSTAGLANDIN F1 ALPHA; DRUG METABOLITE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; THROMBOXANE B2;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MONOCYTES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RADIOIMMUNOASSAY; REFERENCE VALUES; SULFONAMIDES;

EID: 0031868144     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90091-1     Document Type: Article

References (35)

1. 2. J Biol Chem 1989;264: 5768-75.
2. 2+ dependent translocation domain with homology to PKC and GAP. Cell 1991;65:1043-51.
3. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-60.
4. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T. Induction of cyclooxygenase-2 by interleukin-1: evidence for posttranscriptional regulation. J Biol Chem 1994;269:11769-75.
5. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271:1705-12.
6. Reddy ST, Herschman HR. Ligand-induced prostaglandin synthesis requires expression of the TTS10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages. J Biol Chem 1994;269:15473-80.
7. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91: 3228-32.
8. Seibert K, Zhang Y, Leahy K, Scott H, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-7.
9. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995;274:1531-7.
10. Vane J. Towards a better aspirin. Nature 1994;367:215-6.
11. Carr DP, Henn R, Green JR. Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastro-intestinal toxicity of nonsteroidal anti-inflammatory drugs in the rat. Agents Actions 1986;19:374-5.
12. Vane JR, Botting RM. Overview: mechanisms of action of anti-inflammatory drugs. In: Vane J, Botting J, Botting R, editors. Improved non-steroid anti-inflammatory drugs: COX-2 enzyme inhibitors. London: William Harvey and Kluwer Academic; 1996. p. 1-27.
13. Bernareggi A. The pharmacokinetic profile of nimesulide in healthy volunteers. Drugs 1993;46(suppl 1):64-72.
14. Davis R, Brogden RN. Nimesulide: an update of its pharmacodynamic and pharmacokinetc properties, and therapeutic efficacy. Drugs 1994;48:431-54.
15. 2 production in healthy subjects. Thromb Res 1980;17:317-27.
16. 2 in man: identification of twenty urinary metabolites. J Biol Chem 1981;265:8384-93.
17. 2 metabolites in humans. Thromb Res 1987;47:647-56.
18. Boyum A. Isolation of mononuclear cells and granulocytes from human blood: isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest 1968;21(suppl):77-89.
19. 2 in human plasma and urine. Biochim Biophys Acta 1987;918:293-7.
20. 2αuman urine. J Endocrinol Invest 1979;2:173-82.
21. Patrono C, Pugliese F, Ciabattoni G, Patrignani P, Maseri A, Chierchia S, et al. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J Clin Invest 1982;69:231-9.
22. De Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978;235:E97-102.
23. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sc USA 1994;91:11202-6.
24. Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal antiinflammatory drugs. J Pharmacol Exp Ther 1994;271: 927-34.
25. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-8.
26. Vane JR. Inhibition of prostaglandins as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-5.
27. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6.
28. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996;3:927-33.
29. Picot D, Loll PJ, Garavito M. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994;367:243-9.
30. Panara MR, Greco A, Santini G, Sciulli MG, Rotondo MT, Padovano R, et al. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methane-sulphonamide (NS-398) and 5-methane-sulphonamido-6-(2,4-difluorothio-phenyl)-1-indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmacol 1995;116:2429-34.
31. Tavares A, Bishai PM, Bennet A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneimittelforschung 1995;45:1093-5.
32. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissue. FEBS Lett 1993;330:156-60.
33. Frolich JC, Wilson TW, Sweetman BJ, Smigel M, Nies AS, Carr K, et al. Urinary prostaglandins: identification and origin. J Clin Invest 1975;55:763-70.
34. Vio CP, Cespedes C, Gallardo P, Masferrer JL. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997;30:687-92.
35. Garcia Rodriguez LA, Cattarazzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal bleeding associated with ketorolac, other NSAIDs, calcium antagonist and other antihypertensive drugs. Arch Intern Med 1998;158:33-9.